Click here for slides on this topic


Pioglitazone and metformin

Combination sulfonylurea and biguanide for glycemic control in type 2 diabetes.
The following content matched the glossary term: Pioglitazone and metformin

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin

Top

Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-483. A recent position statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) cites metformin as the optimal first-line drug for diabetes treatment. However, the statement acknowledges that limited data exist regarding treatments to be used beyond metformin.

β-cell function preservation after 3.5 years of intensive diabetes therapy

Top

Harrison LB, Adams Huet B, Raskin P, Lingvay I. Beta cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012;35(7):1406-1412. To assess beta-cell function preservation after 3.5 years of intensive therapy with insulin plus metformin (INS group) versus triple oral therapy (TOT group) with metformin, glyburide, and pioglitazone.

Meta-analysis: DPP-4 Inhibitors for Type 2 Diabetes

Top

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Meta-analysis: DPP-4 Inhibitors for Type 2 Diabetes. BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369. Karagiannis and colleagues conducted a systematic review and meta-analysis of 27 studies to evaluate the efficacy of DPP-4 inhibitors for treatment of type 2 diabetes when compared with other antihyperglycemic therapies.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 10, 2012

Top

Daily coverage from the American Diabetes Association 72nd Scientific Sessions June 10, 2012

Beta-cell function preservation, ACCORD-BP, update on insulin therapies for diabetes treatment, pharmacology for diabetes prevention, and more. 

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 8, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 8, 2012

Diabetes and hypoglycemia, clinical management of diabetes, obesity treatment, diabetes in long-term care, and more. 

ADA/European Association for the Study of Diabetes (EASD) Position Statement on Hyperglycemia Management in Type 2 Diabetes

Top

Joint position statement from ADA/EASD with clinical practice recommendations for managing hyperglycemia in type 2 diabetes

NDEI.org Expert Commentary Diabetes Monotherapy DURATION -4 Vivian Fonseca

Top

Expert commentary on diabetes monotherapy in DURATION-4 from Vivian Fonseca, MD

1 2 3 4 5 Next 

Slide Library Results

Search Results for: Pioglitazone and metformin Slides Found: 1
Efficacy of Pioglitazone Plus Sibutramine in Metformin-Intolerant vs Metformin-Tolerant Obese Subjects With Type 2 Diabetes